苏尔法萨拉和托法西提尼布在NSAID耐药反应性关节炎的短期有效性:一项观察性研究
Prakashini Mruthyunjaya1, Debashis Maikap1, Sakir Ahmed1
1Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT Deemed-to-be University, Bhubaneswar, India.
International journal of rheumatic diseases
|July 22, 2025
概括
这项研究比较了NSAID耐药患者对反应性关节炎 (ReA) 的sulfasalazine和tofacitinib. 这两种药物在12周内表现出类似的有效性和安全性,但托法西提尼布提供了更快的症状缓解.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 反应性关节炎 (ReA) 是一种常常在感染后出现的小关节炎,具有严重的慢性化风险.
- 目前对ReA的治疗选择有限,没有批准的疾病修饰性抗风湿药物.
- 了解NSAID耐药ReA的有效治疗方法对于改善患者的治疗结果至关重要.
研究的目的:
- 为了比较sulfasalazine与tofacitinib在NSAID耐药性反应性关节炎患者中的疗效和安全性.
- 通过使用DAREA (Disease Activity Index for the Assessment of Reactive Arthritis) 和其他临床标志物来评估治疗反应.
- 评估这种患者群体中治疗效果的开始和持续时间.
主要方法:
- 一项随机研究包括50名患有NSAID耐药ReA (布朗标准) 的患者,其中25名被分配给sulfasalazine和25名被分配给tofacitinib.
- 主要终点是12周的DAREA;响应被分为完整 (CR),部分 (PR) 或没有响应 (NR).
- 二级终点包括疼痛视觉模拟尺度 (VAS),ESR,CRP,BASFI,MASES和ASDAS-CRP.
主要成果:
- 12周后,46名患者完成了研究;70%是男性,65%是HLA-B27阳性.
- 在12周的DAREA中位数在托法西替尼和硫法萨拉组之间是可比的 (p=0.545).
- 到第4周,托法西提尼布显示CRP,ESR和DAREA的下降速度更快,在DAREA和次要终点 (p<0.001) 两组内都有统计学显著的改善.
结论:
- 苏尔法萨拉和托法西提尼布在NSAID耐药的ReA中表现出可比的12周有效性和安全性.
- 与sulfasalazine相比,托法西提尼布显示治疗反应的开始更快.
- 进一步的研究可能会探索这些药物在REA管理中的长期结果和最佳使用.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
236
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
236
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Inflammatory Bowel Disease IV: Pharmacological Management
196
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
196
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
699
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
699


